Truseltiq Second Targeted Therapy Approved by the FDA for Patients with Advanced or Metastatic Cholangiocarcinoma and the FGFR2 Biomarker
CholangiocarcinomaFDA Approvals, News & Updates
In late May 2021, the FDA approved Truseltiq (infigratinib), a new targeted therapy, for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusion or other rearrangement, as detected by an FDA-approved test.
New Treatment Option for Certain Type of Advanced Bile Duct Cancer
CholangiocarcinomaFDA Approvals, News & Updates
Patients with advanced bile duct cancer, or cholangiocarcinoma (CCA), have few treatment options and a generally poor prognosis. But now, a new medication called Pemazyre (pemigatinib) has been approved by the Food and Drug Administration (FDA) for the treatment of CCA that has spread to other parts of the body or that cannot be removed by surgery, providing a new treatment option for these patients, and perhaps a better outlook for their future.
The Lynx Group Designated “Trusted Partner” of Cholangiocarcinoma Foundation
February 1, 2021 (Cranbury, NJ): The Cholangiocarcinoma Foundation (CCF) designated The Lynx Group (TLG) as a “Trusted Partner,” 1 of only 4 organizations globally. A CCF “Trusted Partner” shares the CCF mission: to find a cure and improve the quality of life for those affected by cholangiocarcinoma (CCA). These 4 esteemed partners are fundamental to the Foundation’s growth and ability to provide high-quality programs and services to the CCA community.
Drugs for Cholangiocarcinoma (Bile Duct Cancer)
Here are the drugs and financial support services available to patients receiving treatment for Cholangiocarcinoma (Bile Duct Cancer).
Comparing Primary Tumor, Metastatic Tumor Tissue, and  Liquid Biopsy in Patients with Intrahepatic Cholangiocarcinoma: Genomic Profiling Study
Genomic alterations (mutations) characteristic of intrahepatic cholangiocarcinoma (CCA) are well-known. In this study, Jeffrey S. Ross, MD, Medical Director, Foundation Medicine, Cambridge, Massachusetts, and colleagues examined whether genomic alterations in intrahepatic CCA of a primary tumor would differ from those found in tissue from a tumor that has metastasized (spread) to other parts of the body and the alterations that are found with liquid biopsy (a test done using a blood sample).
The ClarIDHy Study: IDH1 Mutation Detection in Plasma  Circulating Tumor-Cell DNA and Clinical Response  in Patients with Advanced Intrahepatic Cholangiocarcinoma
The feasibility of IDH1 mutation detection in plasma circulating tumor-cell DNA from patients with intrahepatic cholangiocarcinoma (CCA) was demonstrated.
Combination Immunotherapy with Opdivo and Yervoy in Patients with Advanced Biliary Tract Cancer
The combination of the PD-1 inhibitor Opdivo (nivolumab) and the CTLA-4 inhibitor Yervoy (ipilimumab) has been effective therapy for some types of solid tumor cancers, such as melanoma and lung cancer.
Clinical Trial of Futibatinib, an FGFR Inhibitor, in Patients with Intrahepatic Cholangiocarcinoma Harboring  FGFR2 Gene Fusions or Other Rearrangements
Preliminary results were presented from this phase 2 clinical trial by Lipika Goyal, MD, MPhil, Medical Oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital, Boston, at the 2020 ASCO annual meeting.
Comparing the Combination of 2 Immunotherapies versus Immunotherapy plus Chemotherapy as First-Line Treatment for Patients with Advanced Unresectable Biliary Tract Cancer
In a phase 2 clinical trial, 2 different combinations were studied and compared for use as the first treatments given to patients with cholangiocarcinoma (CCA).
Page 1 of 2
Results 1 - 10 of 16

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Race or Ethnicity
Profession or Role
Primary Interest